| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Other Events
Study did not meet primary endpoint of percentage change from baseline in total abscess and inflammatory nodule (AN) count at Week 16 |
| 27 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
HENDERSON, Nev.--(BUSINESS WIRE)--October 27, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with seriou... |
| 17 Aug 2026 |
8-K: Regulation FD Disclosure
2 Forward-Looking Statements Disclaimer This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
HENDERSON, Nev.--(BUSINESS WIRE)--August 11, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious... |
| 01 Jul 2026 |
8-K: Regulation FD Disclosure
©2026 Zura Bio Ltd. 2 Forward-looking statements disclaimer This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as... |
| 18 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purpose of this Zura Bio Limited 2023 Equity Incentive Plan (the “Plan”) is to promote and closely align the interests of employees, officers, non- employee directors and other service providers of Zura Bio Limited, a Cayman Islands ... |
| 22 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 20, 2026, Someit Sidhu notified Zura Bio Limited (the “Company”) of his decision to resign from the board of directors of the Company effective as of May 21, 2026. Mr. Sidhu’s resignation is not due to any disagreement with the Co... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
HENDERSON, Nev.--(BUSINESS WIRE)--May 7, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and... |
| 23 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This letter sets forth the terms of the separation agreement (the “Agreement”) that Zura Bio Inc. (the “Company”) is offering to you to aid in your employment transition. |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
©2026 Zura Bio Ltd. 2 Forward-looking statements disclaimer This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as... |
| 10 Mar 2026 |
8-K: Regulation FD Disclosure
©2026 Zura Bio Ltd. 2 Forward-looking statements disclaimer This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as... |
| 05 Mar 2026 |
8-K: Regulation FD Disclosure
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress |
| 26 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
Zura Bio Limited, a Cayman Islands exempted company (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (“Leerink Partners”), Piper Sandler & Co. (“Piper Sandler”), and Cantor Fitzgerald & Co. (“Cantor”) ... |
| 23 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors |
| 11 Feb 2026 |
8-K: Regulation FD Disclosure
©2026 Zura Bio Ltd. 2 Forward-looking statements disclaimer This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as... |
| 26 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This letter sets forth the substance of the transition agreement (the “Agreement”) which Zura Bio Limited (the “Company”) is offering to you to aid in your employment transition. |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
©2026 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as... |
| 02 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT NORMALLY TREATS AS PRIVATE AND CONFIDENTIAL. OMISSIONS ARE IDENTIFIED AS [***]. |
| 17 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 11, 2025, Arnout Ploos van Amstel notified Zura Bio Limited (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”) and as a member of the Nominating and Governance Committee of the ... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Continued advancement of two Phase 2 clinical trials evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with topline data expected in the second half of 2026. |
Loading...